Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Dissecting the role of miR-181 genes in normal and pathogenic plasma cells.

FY 2011-12

Summary
The genetic mechanisms that regulate the development, function and maintenance antibody-producing plasma cells are largely unknown. Plasma cells are antibody-producing cells that play an important role in the immune response to foreign pathogens. By producing antibodies that are specific to pathogens our immune system is able to effectively control and eliminate the infection. This study is aimed at determining the role of functional genetic sequences, known as microRNAs, in the regulation of antibody-producing plasma cell development, function and maintenance. MicroRNAs are short non-coding nucleotide sequences that have been shown to play a role in immune cell development and function. Once regarded as "junk" RNAs, microRNAs impact upon the expression of genes in almost half of the human genome. Recently, we discovered that a family of microRNAs is highly expressed in antibody-producing plasma cells. This was followed by the observation that these microRNAs are predicted to silence genes necessary for the development of antibody-producing plasma cells. Thus, we hypothesized that these microRNAs play an integral role in antibody-producing plasma cells. We will test this hypothesis using techniques to eliminate this family of microRNAs during antibody-producing plasma cell development. The findings of this study will provide further insight into the treatment of human diseases caused by the dysregulation of antibody-producing plasma cells, including multiple myeloma (a plasma cell cancer) and systemic lupus erythematosus (commonly known as lupus). Currently there is no cure for either disease. Both are widely treated through non-specific immunosuppressive therapy but relapses occur. Discovering a way to specifically eliminate the development and production of antibody-producing plasma cells would provide a specific and potentially more effective treatment for these diseases.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
242319
Name
Loh Christina
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Dissecting the role of miR-181 genes in normal and pathogenic plasma cells.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
B Cell; Microrna; Plasma Cells; Systemic Lupus Erythematosus
Abstract
The genetic mechanisms that regulate the development, function and maintenance antibody-producing plasma cells are largely unknown. Plasma cells are antibody-producing cells that play an important role in the immune response to foreign pathogens. By producing antibodies that are specific to pathogens our immune system is able to effectively control and eliminate the infection. This study is aimed at determining the role of functional genetic sequences, known as microRNAs, in the regulation of antibody-producing plasma cell development, function and maintenance. MicroRNAs are short non-coding nucleotide sequences that have been shown to play a role in immune cell development and function. Once regarded as "junk" RNAs, microRNAs impact upon the expression of genes in almost half of the human genome. Recently, we discovered that a family of microRNAs is highly expressed in antibody-producing plasma cells. This was followed by the observation that these microRNAs are predicted to silence genes necessary for the development of antibody-producing plasma cells. Thus, we hypothesized that these microRNAs play an integral role in antibody-producing plasma cells. We will test this hypothesis using techniques to eliminate this family of microRNAs during antibody-producing plasma cell development. The findings of this study will provide further insight into the treatment of human diseases caused by the dysregulation of antibody-producing plasma cells, including multiple myeloma (a plasma cell cancer) and systemic lupus erythematosus (commonly known as lupus). Currently there is no cure for either disease. Both are widely treated through non-specific immunosuppressive therapy but relapses occur. Discovering a way to specifically eliminate the development and production of antibody-producing plasma cells would provide a specific and potentially more effective treatment for these diseases.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Loh, Christina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2011-12) | Canada Spends